Helping patients find the bladder cancer resources they deserve
How do we help bladder cancer patients?
Massive Bio offers an independent cancer treatment analysis as well as free clinical trial matching for bladder cancer patients. Our patient advocates work closely with patients to gather information on their current medical status, and then will provide a list of options from available cancer clinical trials close to your home.
We can also provide a second opinion through our Virtual Tumor Board from cancer specialists. The Virtual Tumor Board (VTB) is comprised of highly specialized oncologists from nationally-recognized Cancer Centers of Excellence. In just 7-10 days after receiving your medical records, we can get you a treatment plan without having to travel far distances and use your valuable time.
There are approximately 173 bladder cancer clinical trials that are currently recruiting patients in the United States right now. With such an extensive list, many of them could be beneficial for you. Our team of oncology nurses and our artificial intelligence based clinical trial matching system will find the best option for you.
A study of NKTR-262 in combination with NKTR-214 and with NKTR-214 plus Nivolumab in patients with locally advanced or metastatic solid tumor malignancies.
Pemigatinib + Pembrolizumab vs Pemigatinib alone vs standard of care for Urothelial Carcinoma (FIGHT-205).
Bladder Cancer Facts
Bladder cancer has the 6th most new cases of any cancer type in the United States and the 7th most deaths. Bladder cancer is more than four times more likely to be found in men than women. The average age of a person diagnosed with bladder cancer is 72 and the average age of a patient who dies is 79.
The main risk factors for bladder cancer include family history, inherited gene mutations, chronic bladder infections, Smoking, and long-term use of catheters. Some common symptoms bladder cancer patients experience are blood in the urine, frequent and/or painful urination, inability to urinate, and an urge to urinate when the bladder is not full.
The four most common forms of treatment for bladder cancer patients are surgery, radiation therapy, chemotherapy, and immunotherapy. Many of the screening methods and treatment options will have to be repeated multiple times for the bladder cancer patient. These repeated tests will note the progress that has been made throughout treatment. Sometimes doctors will use surveillance of the urinary tract to check for recurrence.
Lab tests, (advanced genomic testing and urine tests) biopsy, pyelogram, imaging tests (X-ray), MRI, ultrasounds, bone scans, and CT scans are all common forms of screening for bladder cancer. For those who already have a history of bladder cancer, a Cystoscopy or urine cytology can be used to test for a recurrence.
Since 1975, little progress has been made in the prevention and treatment of bladder cancer. The death rate has remained nearly the same and the number of cases has only decreased by a mere 2 people per 100,000. The only visible progress that has been made is the increase of the five-year survival rate from 71% in 1975 to 77% in 2016.
Urothelial carcinoma Flat carcinoma Papillary carcinoma Squamous cell carcinoma Adenocarcinoma Sarcoma
Our team of patient advocates can help guide you to treatment options you might not have been previously aware of. Although you might be new to cancer, we certainly are not. Navigating cancer patients through the tricky path of finding the best treatment is our goal. No two cancer patients are alike, which is why we find treatment for all of our patients based on their specific genomics, location, stage of cancer, and nearly 100 more data points.